Research Article

Biophysical Insight into the Interaction of Human Lysozyme with Anticancer Drug Anastrozole: A Multitechnique Approach

Fahad M. Almutairi¹,¹ Mohammad Rehan Ajmal¹,¹ Adel Ibrahim Al Alawy,¹
Rizwan Hasan Khan²,² and Ali Saber Abdelhameed³

¹Physical Biochemistry Research Laboratory, Biochemistry Department, Faculty of Science, University of Tabuk, P.O. Box 741, Tabuk 71491, Saudi Arabia

²Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India

³Faculty of Pharmacy, King Saud University, Riyadh, Saudi Arabia

Correspondence should be addressed to Fahad M. Almutairi; falrabae@ut.edu.sa and Mohammad Rehan Ajmal; ajmal.rehan@rediffmail.com

Received 26 February 2020; Accepted 19 June 2020; Published 25 August 2020

Academic Editor: Aggelos Avramopoulos

Copyright © 2020 Fahad M. Almutairi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the present study, we employ fluorescence spectroscopy, dynamic light scattering, and molecular docking methods. Binding of anticancer drug anastrozole with human lysozyme (HL) is studied. Binding of anastrozole to HL is moderate but spontaneous. There is anastrozole persuaded hydrodynamic change in HL, leading to molecular compaction. Binding of anastrozole to HL also decreased in vitro lytic activity of HL. Molecular docking results suggest the electrostatic interactions and van der Waals forces played key role in binding interaction of anastrozole near the catalytic site. Binding interaction of anastrozole to proteins other than major transport proteins in blood can significantly affect pharmacokinetics of this molecule. Hence, rationalizing drug dosage is important. This study also points to unrelated effects that small molecules bring in the body that are considerable and need thorough investigation.

1. Introduction

Small ligands are known to intermingle with protein molecules readily [1, 2]. Protein-drug interaction studies are important and central in understanding biological processes. Recently, such studies are hot spots of multidisciplinary research [3, 4]. Drug binding to transport proteins can significantly affect metabolism of drug molecules. Proteins are versatile molecules and perform many different functions in the human body. Human lysozyme (HL) is a small globular protein. HL is found in secretions such as saliva and tears. It is a model protein [5, 6]. Ever since its discovery, lysozyme represented a prototype molecule for understanding the complexity of the protein structure and function [7]. Thus, the study on the interaction of drugs with lysozyme has important significance. Such studies are useful for providing

information on the structural features of the proteins on interaction with drugs and to illuminate the therapeutic effectiveness of drugs [8, 9]. Human lysozyme (HL) is an important enzyme and is part of the body defense against many bacteria. HL is found in tears and saliva [10]. It is a single polypeptide comprising of seven helices and one beta sheet. There are no subunits or prosthetic groups. HL hydrolyze β -1,4-glycosidic linkages between N-acetylmuramic acid and N-acetylglucosamine; these linkages are present in the peptidoglycan cell wall of bacteria [11]. HL causes damage to the bacterial cell wall by degrading the polymer, leading to perforation and bacterial cell lyses [12]. The active site is easily visible in three-dimensional models. Hydrolysis of the cell wall of bacteria is an important component of antimicrobial action of HL [7]. Asp⁵³ and Glu³⁵ are main residues involved in activity [13] while many others are involved in holding ligands to

active sites by hydrogen bonds. Lysozyme from different species seems to function in a similar way [14].

Anastrozole is an anticancer drug [15, 16] Anastrozole is also an important chemotherapy drug used in breast cancer after surgery to reduce the risk and used as hormone therapy [17]. Anastrozole is also an aromatase inhibitor [18]. Hormone sensitive types of cancers are stimulated by the female sex hormones such as estrogen and progesterone [19]. Being used as a hormone modulator, anastrozole is also frequently used in the treatment of pubertal gynecomastia [20]. Taking into consideration the importance of the drug, detailed investigations on anastrozole protein interactions were carried out employing fluorescence, dynamic light scattering, and molecular docking methods. Such knowledge on the mechanism of interaction between the anastrozole and plasma protein is of importance in understanding the pharmacodynamics and pharmacokinetics of anastrozole and anastrozole-designed new therapeutic drugs [21]. Drug binding to proteins may influence transportation, absorption, metabolism, and excretion of drugs [22]. Proteins are flexible molecules and ligand binding can affect the protein hydrodynamics and function; these alterations can be harmful or useful [23–26]. It becomes important to look at different aspects of drug-protein interactions when designing the dosage of the drugs spatially in a multidrug therapy or treatment in comorbid conditions, where the picture can be more complicated; protein binding of drugs not only affects drug pharmacokinetics but it can also affect the protein function. Here in the present study, the drug binds to the model protein and induced conformational alterations are reflected in the decreased catalytic function of the protein in the presence of the drug [27–30]. The interaction of anastrozole with the protein has been investigated under simulated physiological conditions using different optical techniques. Such studies can be extended to other important transporter proteins to give a more generalized view [31–33]. Investigation of interaction of anastrozole with HL assumes importance in life sciences, chemistry, and clinical medicine. The measures are of particular interest in clinical and pharmaceutical assessment.

2. Materials and Methods

Human lysozyme and anastrozole were products of Sigma-Aldrich. All other reagents used were of analytical grade.

2.1. Sample Preparation. All experiments were carried out in 20 mM sodium phosphate buffer of pH 7.4. HL was extensively dialyzed in buffer. Protein stock solutions (2.5 mg/ml) were prepared. The concentration of native protein in 20 mM phosphate buffer was determined using a double-beam UV-visible spectrophotometer (Cary 60, Agilent Technologies), the value of extinction coefficient used is $\epsilon_M = 37970 \text{ M}^{-1} \cdot \text{cm}^{-1}$ at 280 nm [34]. 5 mg/ml anastrozole solution was prepared by weight/volume (w/v) in absolute alcohol [35].

2.2. Fluorescence Measurements. Cary Eclipse Fluorescence Spectrophotometer with thermal controller (Agilent Technologies) was used to measure the fluorescence emission

spectra of HL. Emission spectra were recorded in the range of 300–500 nm with the excitation and emission slit width of 5 nm and 10 nm, respectively. Anastrozole is titrated into 5 μM HL so as to obtain the range of drug-to-protein molar ratio of $d/p = 0$ to $d/p = 10$. Drug titrations were performed at 310 K, emission spectra were recorded, and data were plotted at 340 nm. The decrease in fluorescence intensity at 340 nm was analyzed according to the Stern–Volmer equation (equation (1)) [36, 37].

$$\frac{F_0}{F} = K_{sv}[Q] + 1 = k_q\tau_0[Q] + 1, \quad (1)$$

where F_0 and F are the fluorescence intensities in the absence and presence of quencher (anastrozole). K_{sv} is the Stern–Volmer quenching constant, k_q is the bimolecular rate constant of the quenching reaction, and τ_0 the average integral fluorescence life time biomolecules without quencher, which is $\sim 10^{-8}$ sec.

Binding constants and number of binding sites were obtained from modified Stern–Volmer equation (equation (2)) [38].

$$\text{Log} \left(\left(\frac{F_0}{F} \right) - 1 \right) = \log K_b + n \log [Q], \quad (2)$$

where F_0 and F are the fluorescence intensities in the absence and presence of quencher (anastrozole), K_b is the binding constant, and n is the binding stoichiometry. Gibbs–Helmholtz equation (equation (3)) was used for calculating thermodynamic parameters of ligand binding [39, 40].

$$\Delta G^\circ = -RT \ln K_b, \quad (3)$$

where K_b is the binding constant at temperature T , ΔG° is free energy change, R is a gas constant ($1.987 \text{ cal} \cdot \text{mol}^{-1} \cdot \text{K}^{-1}$) [41], and T is the absolute temperature (K).

2.3. Dynamic Light Scattering Measurements. DLS measurements were made using Zetasizer nano ZSP dynamic light scattering equipment (Malvern Instruments) equipped with a temperature-controlled sampler. DTS1070 folded capillary cells were used for size measurements. HL alone (10 μM) and HL solution with anastrozole (100 μM) was incubated for 2 hours before measurement. Measurements were then made, and hydrodynamic radius (nm) data were obtained using dynamics Zetasizer software provided with the instrument.

2.4. Molecular Docking. Anastrozole docking to HL was performed using 4.2.6 software (<http://autodock.scripps.edu>) [42–46]. Crystal structure of HL was obtained from Brookhaven Protein Data Bank PDB Id (1REX) and the coordinate 3D SDF file of anastrozole (CID 2794) was obtained from PubChem compound search. During docking calculations, all torsional bonds of anastrozole were set free to obtain possible conformation of the drug that binds to the protein, whereas HL was held rigid, and polar hydrogen was added using autodock tools. Grid size was set so as to cover all active site residues, and grid size was set at 126, 126, and

126 along X, Y, and Z axes. Auto dock rigid parameters were selected for protein chains and the ligand was allowed for flexible rotation. Lamarckian genetic algorithm (LGA) with GA population size 150 and maximum number of 2500000 energy evolutions were selected; the lowest energy conformation of the largest cluster of every docking simulation was extracted and analyzed. Best solution based on docking score was retained for further analysis and the docked conformation is visualized with Discovery Studio 3.5 Visualizer.

2.5. Muramidase Activity. Rate of loss of turbidity of *M. lysodeikticus* suspension was obtained using the absorbance value at 450 nm. 2 μ M HL was incubated with various molar concentrations of anastrozole at 298 K for two hours and then 10 μ L from each of these solutions was added to 2990 μ L of suspension of 0.3 mg/ml *M. lysodeikticus* in a quartz cuvette placed in the cuvette holder maintained at 298 K in the cuvette holder of Cary 60 double-beam UV-Vis spectrophotometer (Agilent Technologies). Decrement in absorbance values at 450 nm with time was monitored and used for the activity calculations [5]. Data obtained with the HL alone were assumed to be 100% and data obtained in the presence of anastrozole were organized with respect to the value obtained with HL alone that is considered as a reference. IC50 values are calculated using online software (<https://www.aatbio.com/tools/ic50-calculator>).

3. Results and Discussion

3.1. Fluorescence Spectroscopy. To assess the binding considerations to protein molecule, steady state fluorescence quenching measurements were done and data were analyzed. The fluorescence spectroscopy technique has been widely used to study protein-ligand communications. Proteins have aromatic amino acid residues tyrosine, tryptophan, and phenylalanine. They serve as internal fluorophores. Tryptophan contribution in intrinsic fluorescence of proteins is maximum. Fluorescence quenching data for proteins can be engaged to obtain information on the protein-drug binding course. Ligand binding characteristics of ligand to the protein can be obtained. The interaction contrivances can be worked out using the fluorescence quenching data of the protein. In the present study fluorescence emission intensity of HL decreased proportionally with increasing drug concentrations (Figure 1).

There is sizeable decrease in fluorescence intensity of HL upon the titration of anastrozole. During the titration, the emission maxima remained unmoved. The fluorescence quenching data was analyzed according to the Stern-Volmer equation (equation (1)), and the bimolecular quenching constant for the interaction was calculated to be of the order of 10^{11} (Table 1) which is greater than the maximum collision quenching constant value obtained for various biomolecules $2 \times 10^{10} \text{ M}^{-1} \text{ s}^{-1}$. Moreover, Stern-Volmer quenching constant values obtained from linear Stern-Volmer plots are shown in Figure 2.

FIGURE 1: Fluorescence quenching of HL induced by anastrozole at 310 K. The concentration of HL was 5 μ M and the concentration of anastrozole varied from 0 to 50 μ M. The intrinsic fluorescence of the protein was measured in 20 mM sodium phosphate buffer, pH 7.4 at 310 K upon excitation at 280 nm.

Fluorescence quenching records were analyzed according to the modified Stern-Volmer equations (equation (2)) and binding constant and binding stoichiometry for the interaction of anastrozole was calculated with the slopes and intercept of the linear plots (Figure 3).

Binding constant is noteworthy in pharmacology and medicine. The binding constant of drug to proteins can significantly impact the transportation and absorption of drug molecules. Drug binding can affect the metabolism of drug compounds. The binding constant of HL anastrozole interaction was found to be near the order of 10^4 at 310 K; binding stoichiometry was calculated near to 1 for the binding of anastrozole to HL at the temperature studied. Binding process of ligands to macromolecules involve many interactive forces including hydrogen bonding, hydrophobic interactions, van der Waals forces, and electrostatic interactions. Although individually these forces are weak, cumulatively these forces have huge impact on the behavior and function of ligand-protein interaction process. Thermodynamic calculations were performed using linear first law of thermodynamics and values for standard Gibbs free energy change were calculated using equation (3); the values are reported in Table 1.

We obtained negative value of Gibbs standard free energy change. The negative free energy change indicates spontaneity of interaction of anastrozole to HL. The decrement in free energy can be attributed to compensatory alterations in molecular hydrodynamics of protein upon ligand binding. Also, there occurs reformation of non-covalent interactions when ligand molecules entered the binding pocket in protein molecule.

TABLE 1: Binding parameters of anastrozole interaction to HL in 20 mM phosphate buffer of pH 7.4 at 310 K temperature obtained and calculated from fluorescence quenching data.

T (K)	K_{SV} ($\times 10^3 M^{-1}$)	R^2	K_q ($\times 10^{12} M^{-1}s^{-1}$)	K_b ($\times 10^3 M^{-1}$)	R^2	n	ΔG (kcal.mol $^{-1}$)	ΔH (kcal.mol $^{-1}$)	ΔS (cal.mol $^{-1}.K^{-1}$)
310	9.20	0.99	9.20	9.66	0.99	1.00	-5.65	-11.15	-19.30

FIGURE 2: Stern-Volmer plots for fluorescence quenching of HL induced by anastrozole at 310 K. The concentration of HL was $5 \mu M$ and the concentration of anastrozole varied from 0 to $50 \mu M$. The intrinsic fluorescence of the protein was measured in 20 mM sodium phosphate buffer, pH 7.4 at 310 K upon excitation at 280 nm.

3.2. Dynamic Light Scattering (DLS). DLS is an important technique to study the changes in the molecular size of the protein in the solution. The hydrodynamic radius (R_h) value at 298 K for HL at pH 7.4 was found to be 2 nm, which is unswerving with the earlier reports [47], R_h values were found to dwindle to 1.8 nm when HL was incubated with anastrozole (1:10) concentration. This shrink in R_h values may arise due to collapse of protein on drug binding. Ligand binding encourage rearrangement of conformational state and alterations in the protein upon anastrozole. Ligand binding may account for the decrease in hydrodynamic radii of HL and leading to molecular shrinkage reflecting in decrease in hydrodynamic radius of HL in presence of anastrozole. DLS measures overall total hydrodynamic size changes. Molecular shrinkage and expansion can be studied but specific region or domains cannot be studied. DLS results indicate size changes in the presence of anastrozole.

3.3. Molecular Docking. Molecular docking study was performed as described in section 2.4 to locate the binding

FIGURE 3: Modified Stern-Volmer plots for fluorescence quenching of HL induced by anastrozole at 310 K. The concentration of HL was $5 \mu M$ and the concentration of anastrozole varied from 0 to $50 \mu M$. The intrinsic fluorescence of the protein was measured in 20 mM sodium phosphate buffer, pH 7.4 at 310 K upon excitation at 280 nm.

region of anastrozole on the HL molecule. Molecular docking results suggested the anastrozole interacts with the HL via electrostatic and van der Waals interactions (Figures 4(a)–4(c)).

Amino acid residues found to interact with anastrozole are listed in Table 2 and there is involvement of polar amino acid residues in the interaction process while the free energy for the binding process from the docking results is $-6.64 \text{ kcal.mol}^{-1}$. Free energy change obtained from docking results although has same sign but values may differ because docking considers the backbone movements and overall fit of ligand into the binding pocket and protein remain rigid and the ligand is flexible. Changes in fluorescence emission are measured, and data are analyzed to obtain binding information. Fluorescence data are mainly the outcome of changes around fluorophores present in proteins.

As it is observed that amino acid residues are involved in binding of substrate to active site on the HL molecule, we further investigated the effect of anastrozole interaction on in vitro lytic action of lysozyme.

FIGURE 4: Molecular docking results of HL molecule with anastrozole. (a) Anastrozole is shown in a stick representation and HL is represented with ribbon model. (b) Detailed view of the docking poses of HL-anastrozole complex. (c) 2D plot of interaction of anastrozole with HL.

TABLE 2: Molecular docking parameters obtained from HL-anastrozole binding.

Amino acid residues	Force involved	ΔG (kcal.mol ⁻¹)
Arg-113, Ala-111, Val-110, Glu-35 Trp-109, Arg-107, Ala-108, Gln-104 Gln-58, Val-99, Ile-59, Asp-53, Asn-60 Tyr-63, Trp-64	Electrostatic interactions and van der Waals interaction	-6.64

3.4. Muramidase Activity. To test the lytic activity of HL in the presence of anastrozole, linear decrease of turbidity with time was used for the calculation of percentage activity in the HL samples with and without anastrozole. Enzymatic activity was found to decrease with increased anastrozole concentration and IC₅₀ was found to be 10.78 (Figure 5).

It was found that the binding of the drug anastrozole brought about the conformational changes in the protein that negatively affected the lytic action of the protein. Decrease in the activity also signifies the effect of drug binding to proteins and far reaching effects on its structure and function.

FIGURE 5: Activity results of HL with anastrozole; native HL muramidase activity is taken as 100%, at pH 7.4 and temperature of 298 K.

4. Conclusion

The present study details the interaction of anastrozole with the model protein HL. Ligand binding effects on protein conformation and activity were studied. The binding course of anastrozole to HL is found to be spontaneous. Binding of anastrozole to HL induced hydrodynamic changes in HL and caused the molecule of HL to contract. Owing to topology alterations and involvement of amino acids near the catalytic site in drug binding, decreased in vitro lytic activity of HL was noticed. Drug-induced changes are plausible for the decreased catalytic efficiency of the protein in the presence of drug in in vitro studies. Anastrozole interacts with HL via hydrophobic and hydrogen bonding interactions. This study reflects the importance and multimodal effects of ligand binding to proteins. Therefore, understanding such interactions and drug binding parameters is imperative. The interaction of the HL with anastrozole can pave the way for the advancement of therapeutic and diagnostic strategies in conditions where disease is associated with protein function alteration and also in designing new molecules or studying drug repurposing.

Data Availability

Data used to support the findings of this study are available from the corresponding author upon request. No third party data were used in this work.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors would like to extend their sincere appreciation to the facilities provided by the Deanship of Scientific

Research (DSR) and University of Tabuk for funding this research group project (0280-1440-S).

References

- [1] M. R. Ajmal, N. Zaidi, P. Alam et al., "Insight into the Interaction of antitubercular and anticancer compound clofazimine with human serum albumin: spectroscopy and molecular modelling," *Journal of Biomolecular Structure and Dynamics*, vol. 35, no. 1, pp. 46–57, 2017.
- [2] X. Hu and H. Li, "Force spectroscopy studies on protein-ligand interactions: a single protein mechanics perspective," *FEBS Letters*, vol. 588, no. 19, pp. 3613–3620, 2014.
- [3] O. Keskin, A. Gursoy, B. Ma, and R. Nussinov, "Towards drugs targeting multiple proteins in a systems biology approach," *Current Topics in Medicinal Chemistry*, vol. 7, no. 10, pp. 943–951, 2007.
- [4] Y. Zhang, M. Zhang, Y. Wang et al., "Protein-ligand interaction guided discovery of novel VEGFR-2 inhibitors," *Journal of Biomolecular Structure and Dynamics*, vol. 38, no. 9, pp. 2559–2574, 2019.
- [5] M. R. Ajmal, S. K. Chaturvedi, N. Zaidi et al., "Biophysical insights into the interaction of hen egg white lysozyme with therapeutic dye clofazimine: modulation of activity and SDS induced aggregation of model protein," *Journal of Biomolecular Structure and Dynamics*, vol. 35, no. 10, pp. 2197–2210, 2017.
- [6] S. Leone, J. Fonderico, C. Melchiorre, A. Carpentieri, and D. Picone, "Structural effects of methylglyoxal glycation, a study on the model protein MNEI," *Molecular and Cellular Biochemistry*, vol. 451, no. 1–2, pp. 165–171, 2019.
- [7] N. Saadati-Eskandari, L. Navidpour, P. Yaghmaei, and A. Ebrahim-Habibi, "Amino acids as additives against amorphous aggregation: in vitro and in silico study on human lysozyme," *Applied Biochemistry and Biotechnology*, vol. 189, no. 1, pp. 305–317, 2019.
- [8] M. R. Ajmal, A. S. Abdelhameed, P. Alam, and R. H. Khan, "Interaction of new kinase inhibitors cabozantinib and tofacitinib with human serum alpha-1 acid glycoprotein. A comprehensive spectroscopic and molecular Docking approach," *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, vol. 159, pp. 199–208, 2016.
- [9] B. Karaman and W. Sippl, "Computational drug repurposing: current trends," *Current Medicinal Chemistry*, vol. 26, no. 28, pp. 5389–5409, 2019.
- [10] M. I. Khan, D. Dowarha, R. Katte, R.-H. Chou, A. Filipek, and C. Yu, "Lysozyme as the anti-proliferative agent to block the interaction between S100A6 and the RAGE V domain," *PLoS One*, vol. 14, no. 5, Article ID e0216427, 2019.
- [11] T. Durek, V. Y. Torbeev, and S. B. H. Kent, "Convergent chemical synthesis and high-resolution x-ray structure of human lysozyme," *Proceedings of the National Academy of Sciences*, vol. 104, no. 12, pp. 4846–4851, 2007.
- [12] B. Masschalck and C. W. Michiels, "Antimicrobial properties of lysozyme in relation to foodborne vegetative bacteria," *Critical Reviews in Microbiology*, vol. 29, no. 3, pp. 191–214, 2003.
- [13] M. Muraki, S. Goda, H. Nagahora, and K. Harata, "Importance of van der Waals contact between Glu 35 and Trp 109 to the catalytic action of human lysozyme," *Protein Science: A Publication of the Protein Society*, vol. 6, no. 2, pp. 473–476, 1997.
- [14] K. Harata, M. Muraki, Y. Hayashi, and Y. Jigami, "X-ray structure of glu 53 human lysozyme," *Protein Science*, vol. 1, no. 11, pp. 1447–1453, 1992.
- [15] A. S. Zidan, O. A. Sammour, M. A. Hammad et al., "Formulation of anastrozole microparticles as biodegradable

- anticancer drug carriers," *AAPS PharmSciTech*, vol. 7, no. 3, pp. E38–E46, 2006.
- [16] R. Punith and J. Seetharamappa, "Spectral characterization of the binding and conformational changes of serum albumins upon interaction with an anticancer drug, anastrozole," *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, vol. 92, pp. 37–41, 2012.
 - [17] R. Jakesz, W. Jonat, M. Gnant et al., "Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial," *The Lancet*, vol. 366, no. 9484, pp. 455–462, 2005.
 - [18] P. E. Löunning, "Aromatase inhibition for breast cancer treatment," *Acta Oncologica*, vol. 35, no. sup5, pp. 38–43, 1996.
 - [19] P. T. Cagle, D. R. Mody, and M. R. Schwartz, "Estrogen and progesterone receptors in bronchogenic carcinoma," *Cancer Research*, vol. 50, no. 20, pp. 6632–6635, 1990.
 - [20] F. G. Riepe, I. Baus, S. Wiest, N. Krone, W. G. Sippell, and C.-J. Partsch, "Treatment of pubertal gynecomastia with the specific aromatase inhibitor anastrozole," *Hormone Research in Paediatrics*, vol. 62, no. 3, pp. 113–118, 2004.
 - [21] S. W. Grimm and M. C. Dyroff, "Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase," *Drug Metabolism and Disposition: The Biological Fate of Chemicals*, vol. 25, no. 5, pp. 598–602, 1997.
 - [22] J. Caldwell, I. Gardner, and N. Swales, *An Introduction to Drug Disposition: The Basic Principles of Absorption, Distribution, Metabolism, and Excretion*, Sage Publications, Thousand Oaks, CA, USA, 1995.
 - [23] I. Elfaki, A. Knitsch, A. Matena, and P. Bayer, "Identification and characterization of peptides that bind the PPIase domain of Parvulin17," *Journal of Peptide Science*, vol. 19, no. 6, pp. 362–369, 2013.
 - [24] M. R. Ajmal, S. Nusrat, P. Alam et al., "Interaction of anticancer drug clofarabine with human serum albumin and human α -1 acid glycoprotein. Spectroscopic and molecular docking approach," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 135, pp. 106–115, 2017.
 - [25] M. M. Babu, R. van der Lee, N. S. de Groot, and J. Gsponer, "Intrinsically disordered proteins: regulation and disease," *Current Opinion in Structural Biology*, vol. 21, no. 3, pp. 432–440, 2011.
 - [26] M. Jaremko et al., "The structural insight into the cis/trans isomerisation process in Psychrophilic archaeon the atomic level: NMR studies of the Pin protein from the archaeon *Cenarchaeum symbiosum*: P03. 66," *The Febs Journal*, vol. 278, 2011.
 - [27] I. O. A. Elfaki, R. Mir, F. M. Almutairi, and F. M. Abu-Duhier, "Cytochrome P450: polymorphisms and roles in cancer, diabetes and atherosclerosis," *Asian Pacific Journal of Cancer Prevention: APJCP*, vol. 19, no. 8, p. 2057, 2018.
 - [28] M. R. Ajmal, S. Nusrat, P. Alam et al., "Differential mode of interaction of ThioflavinT with native β structural motif in human α 1-acid glycoprotein and cross beta sheet of its amyloid: biophysical and molecular docking approach," *Journal of Molecular Structure*, vol. 1117, pp. 208–217, 2016.
 - [29] F. Wang, S. Sheng, X. Ge, H. Huang, and Q. Ma, "Exploring the interaction between milrinone drug and lysozyme by fluorescence spectroscopy and differential scanning calorimetry," *Journal of Thermal Analysis and Calorimetry*, vol. 135, no. 5, pp. 2849–2856, 2019.
 - [30] M. Siddiqi, S. Nusrat, P. Alam et al., "Investigating the site selective binding of busulfan to human serum albumin: biophysical and molecular docking approaches," *International Journal of Biological Macromolecules*, vol. 107, pp. 1414–1421, 2018.
 - [31] G. U. Nienhaus, *Protein-Ligand Interactions: Methods and Applications*, Vol. 305, Springer, Berlin, Germany, 2005.
 - [32] U. Kragh-Hansen, "Molecular aspects of ligand binding to serum albumin," *Pharmacological Reviews*, vol. 33, no. 1, pp. 17–53, 1981.
 - [33] F. A. de Wolf and G. M. Brett, "Ligand-binding proteins: their potential for application in systems for controlled delivery and uptake of ligands," *Pharmacological Reviews*, vol. 52, no. 2, pp. 207–236, 2000.
 - [34] S. Nusrat, M. K. Siddiqi, M. Zaman et al., "A comprehensive spectroscopic and computational investigation to probe the interaction of antineoplastic drug nordihydroguaiaretic acid with serum albumins," *PLoS One*, vol. 11, no. 7, Article ID e0158833, 2016.
 - [35] J. Pis and R. Smrz, "Process for purification of anastrozole," Google Patents, 2010.
 - [36] J. R. Lakowicz, *Principles of Fluorescence Spectroscopy*, Springer Science & Business Media, Berlin, Germany, 2013.
 - [37] S. Siddiqi, F. Ameen, I. Jahan, S. M. Nayeem, and M. Tabish, "A comprehensive spectroscopic and computational investigation on the binding of the anti-asthmatic drug triamcinolone with serum albumin," *New Journal of Chemistry*, vol. 43, no. 10, pp. 4137–4151, 2019.
 - [38] P.-l. Wang, Z. Sun, X.-J. Lv et al., "A homologues prediction strategy for comprehensive screening and characterization of C21 steroids from Xiao-ai-ping injection by using ultra high performance liquid chromatography coupled with high resolution hybrid quadrupole-orbitrap mass spectrometry," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 148, pp. 80–88, 2017.
 - [39] S. Khatun, F. A. Riyazuddeen, and F. A. Qais, "Characterization of the binding of triprolidine hydrochloride to hen egg white lysozyme by multi-spectroscopic and molecular docking techniques," *Journal of Molecular Liquids*, vol. 269, pp. 521–528, 2018.
 - [40] S. Yasmeen, Riyazuddeen, S. Khatun, and F. A. Qais, "Characterization of interactions between cromolyn sodium and bovine serum albumin by spectroscopic, calorimetric and computational methods," *Journal of Biomolecular Structure and Dynamics*, vol. 38, no. 3, pp. 722–732, 2020.
 - [41] M. R. Moldover, J. P. M. Trusler, T. J. Edwards, J. B. Mehl, and R. S. Davis, "Measurement of the universal gas ConstantRUsing a spherical acoustic resonator," *Physical Review Letters*, vol. 60, no. 4, pp. 249–252, 1988.
 - [42] P. Alam, S. K. Chaturvedi, T. Anwar et al., "Biophysical and molecular docking insight into the interaction of cytosine β -D arabinofuranoside with human serum albumin," *Journal of Luminescence*, vol. 164, pp. 123–130, 2015.
 - [43] D. S. Goodsell, "Computational docking of biomolecular complexes with AutoDock," *Cold Spring Harbor Protocols*, vol. 2009, no. 5, 2009.
 - [44] S. M. Rizvi, S. Shakil, and M. Haneef, "A simple click by click protocol to perform docking: AutoDock 4.2 made easy for non-bioinformaticians," *EXCLI Journal*, vol. 12, pp. 831–57, 2013.
 - [45] N. El-Hachem, B. Haibe-Kains, A. Khalil, F. H. Kobeissy, and G. Nemer, "AutoDock and AutoDockTools for protein-ligand docking: beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a case study," in *Methods in Molecular Biology*, pp. 391–403, Springer, Berlin, Germany, 2017.
 - [46] G. M. Morris, R. Huey, and A. J. Olson, "Using autodock for ligand-receptor docking," *Current Protocols in Bioinformatics*, vol. 24, no. 1, pp. 8.14. 1–8.14. 40, 2008.
 - [47] S. Nusrat, A. Masroor, M. Zaman et al., "Interaction of catecholamine precursor l-Dopa with lysozyme: a biophysical insight," *International Journal of Biological Macromolecules*, vol. 109, pp. 1132–1139, 2018.